No Data
Enwei Pharmaceutical (301331.SZ): The wholly-owned subsidiary has obtained the renewed "Pharmaceutical Production License".
On March 25, Gelonghui reported that Enwei Pharmaceutical (301331.SZ) announced that its wholly-owned subsidiaries, Henan Xinxin Pharmaceutical Co., Ltd. (referred to as: Xinxin Pharmaceutical), SiChuan Enwei Pharmaceutical Co., Ltd., and Enwei (Jiangxi) Pharmaceutical Co., Ltd. have recently obtained the "Pharmaceutical Production License" reissued by the pharmaceutical regulatory authorities.
Enwei Medicine (301331.SZ): Currently, there is no production or sales of medical beauty masks.
On March 18, Gelonghui reported that Enwei Pharmaceuticals (301331.SZ) stated on the investor interaction platform that the company currently does not produce or sell medical beauty facial mask products.
Enwei Medical (301331.SZ): The company's e-commerce Business has consistently maintained rapid growth.
On March 4, Gelonghui reported that Enwei Pharmaceutical (301331.SZ) stated on the investor interaction platform that the company's e-commerce Business has been maintaining rapid growth, especially several daily chemical products favored by Consumers, which have seen explosive sales. Some products from the Men's Care line of Jieryin have gone out of stock on certain platforms, and the company's e-commerce department is currently working to replenish stock.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Enwei Pharmaceuticals: 2024 Annual Results Forecast
Enwei Pharmaceutical (301331.SZ): Henan's first batch of key varieties, including heat-clearing and detoxifying oral liquid, antiviral oral liquid, and other products, has been mass-produced and is now fully available for sale.
On January 8, Gelonghui reported that Enwei Pharmaceutical (301331.SZ) stated on the investor interaction platform that the company's products including Compound Paracetamol and Amantadine Tablets, Compound Silver Qiao Amine Capsules, and Children's Paracetamol and Yellow Nasal Capsules are suitable for relieving symptoms of common and epidemic influenza. Children's Cough and Wheezing Granules have functions of promoting lung function, clearing heat, stopping cough, and expelling phlegm. The products are mainly sold through offline OTC and online e-commerce channels. The company's key products from Henan, including Heat-clearing and Detoxifying Oral Liquid, Anti-Viral Oral Liquid, etc., have been mass-produced and are fully available for sale.
Enwei Pharmaceutical Co., Ltd. (SZSE:301331) Stock's On A Decline: Are Poor Fundamentals The Cause?